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Abstract 
Objective: To review available literature regarding pharmacogenomics (PGx) effects on the metabolism of irinotecan by the UGT1A1 
gene and the resulting dose adjustments based on PGx genetic variant.  
 
Summary: Irinotecan is a chemotherapy agent commonly used in treatment of various cancers such as metastatic colorectal cancer 
(mCRC) and others. The extent of decreased function of UGT1A1 varies based on genotype so irinotecan dose adjustments may be 
needed. Those with UGT1A1 homozygous *28/*28 genotype may experience 70% reduction in activity, while heterozygous genotypes 
with *1/*28 may only experience 30% loss. UGT1A1*6 variants may also play a role in decreased function. The incidence of *28 and *6 
alleles varies among ethnic populations resulting in the need for dosage adjustments to avoid toxicities. 
 
Conclusion: These findings add to a growing body of literature that suggest patients with UGT1A1 *28 or *6 variant alleles benefit from 
lower doses of irinotecan. However, due to the heterogeneity of currently available studies, more evidence that investigates various 
regimens in different patient populations is needed to determine the most appropriate dosing strategies. Although other factors, as 
well as efficacy considerations will likely influence clinical decision making, genotype may be an important factor when determining 
dose. 
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Introduction 
Irinotecan is a chemotherapy agent commonly used in 
treatment of various cancers such as metastatic colorectal 
cancer (mCRC) among others. Irinotecan is a prodrug and is 
converted into its active metabolite, SN-38 via hydrolysis. SN-
38 is then inactivated by UDP-glucuronosyltransferase 
(UGT1A1) through glucuronidation.1 (Figure I) The UGT1A1 
gene is diverse with over 135 genetic variants reported.2 
UGT1A1*1 is the wild type allele and represents normal 
function, while other alleles such as *28 and *6 result in 
decreased function of the enzyme. These variant alleles are 
observed in conditions associated with hyperbilirubinemia such 
as Crigler-Najjar and Gilbert’s syndrome, since UGT1A1 also 
plays a role in bilirubin metabolism.3 The extent of decreased 
function varies based on genotype. Those with homozygous 
*28/*28 genotype may experience 70% reduction in UGT1A1 
activity, while heterozygous genotypes with *1/*28 may only 
experience a 30% loss.4 The incidence of these two alleles varies 
among ethnic populations. The *28 allele is more commonly  
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found in Caucasians and African Americans, while the *6 allele 
is often seen in Asian populations.5 (Table I) With decreased 
activity of UGT1A1, the serum concentration of SN-38 increases 
and leads to possible increased risk of toxicity such as severe 
neutropenia, hepatotoxicity or diarrhea. (Figure II) 
 
Due to the pivotal role UGT1A1 plays in the metabolism of 
irinotecan, the FDA amended the package insert in 2005 to 
recommend a reduction in the initial dosage if patients are 
homozygous for the *28 allele.6  Since then, many studies have 
emerged solidifying the relationship between UGT1A1 
genotype and incidence of adverse effects with administration 
of irinotecan. A meta-analysis by Yang et al.7 analyzing 38 
studies found that the odds ratio for severe toxicity for *28 
homozygous genotypes compared to wild type genotypes was 
3.50, while for *6 homozygotes it was 3.03. However, a lack of 
guidance exists to provide specific initial dosing 
recommendations for clinicians, resulting in a need to analyze 
currently available literature. 
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Figure I 
Metabolism of Irinotecan 
 
 
 
 
 
Figure II 
Concentration/Time SN-38G/SN-38 Ratio Profile of Genotypes 
 
Key: 6/6 = *28/*28, 6/7 = *1/*28, *1/*1 = 7/7 
(#Higher concentrations of SN-38 likely results in increased incidence of toxicity) 
 
 
 
 
Table I 
UGT1A1*28 and UGT1A1*6 Allele Frequencies 
 
 
 
 
 
 
UGT1A1*28 Allele Frequencies4 
Caucasian 0.26-0.31 
African American  0.42-0.56 
Asian 0.09-0.16 
UGT1A1*6 Allele Frequencies4 
Japanese 0.13 
Korean  0.23 
Chinese 0.23 
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Methods 
The objective of the study was to gather and evaluate evidence 
available for appropriate irinotecan dosages in patients with 
*28 and *6 alleles to provide guidance for clinicians. A review 
of the literature was conducted in May 2019 using PubMed, 
Cochrane Library and Google Scholar, using the keywords 
“irinotecan”, “UGT1A1”, “dose-finding”, “dose”. Studies were 
evaluated based on inclusion and exclusion criteria described 
below. For each study, a single investigator performed data 
abstraction to include study population, sample size, genotype 
distribution, therapy regimen and primary/secondary 
endpoints. 
 
Inclusion criteria: 
 
 Treatment regimen included irinotecan 
 Patients in experimental group had *28 or *6 alleles 
present 
 Study evaluated effects of various doses on safety 
profile of irinotecan 
 May be prospective or retrospective, but must 
include human subjects 
 May take place in any country 
 May include patients with any cancer type 
 
Exclusion criteria: 
 
 Study took place over 15 years ago 
 Published in any other language other than English 
 Only the abstract was available in publication 
 Review article, editorials or opinion articles contained 
no original research 
 Study only establishes relationship between genotype 
and incidence of adverse effects without 
consideration of dose 
 
Results 
Eight studies in total were included for analysis.8-15 All were 
phase I prospective dose finding studies except for Lu et al14 
which was a retrospective chart review. Most of the studies 
included investigated patients with metastatic colorectal 
cancer, however two studies included patients with other types 
of malignancies.11,13 Goetz et al11 included patients with 
metastatic or locally advanced cancers with a variety of 
different tumor types such as breast, stomach and bladder. 
Innocenti et al13 studied patients with solid tumors or 
lymphomas refractory to standard therapy and tumor types 
were classified as gastrointestinal, lung or other. The sample 
size ranged from 48 to 107 participants. 6 out of 8 studies 
investigated the *1 and *28 alleles only. 8,9,11,13-15 All included 
patients with *1/1, *1/*28 and *28/*28 genotypes except the 
two studies by Toffoli et al8,15 who excluded *28/*28 patients, 
due to low sample sizes. Satoh et al10 and Kim et al12 also 
included the *6 variant allele, which is more prevalent in Asian 
countries. In Kim’s study, there were two patients that 
displayed the *6/*28 genotype, which they concluded would be 
functionally similar to a homozygous*28/*28 genotype. 
Inclusion criteria in all studies included parameters indicating 
adequate renal and hepatic function, such as serum creatinine 
less than 1.5 mg/dL and liver enzymes that were within normal 
limits. Some studies required patients to have an absolute 
neutrophil count (ANC) of greater than 1,500-2,000 to rule out 
pre-existing neutropenia. 8,9,11,12,13,15 Other studies had 
additional criteria such as a wash-out period from prior 
chemotherapy or radiation that ranged from 3 weeks to 6 
months to the time of study initiation.10-12 
 
Finding the maximum tolerated dose (MTD) and dose limiting 
toxicities (DLT) was the primary endpoint in all studies. A 3+3 
design (Figure III) was used in most studies to find MTD, except 
in Satoh et al10 which used the continual reassessment method 
(CRM) and Lu et al14 which was a retrospective chart review. 
Definitions of MTD varied between studies. Marcuello et al9 and 
Goetz et al11 defined MTD as the dose level below which 2/6 
patients experienced a DLT, while in Kim’s study it was the level 
at which 2/6 patients experienced DLT. In Innocenti et al13, it 
was defined as the level at which less than 4/12 patients 
experience a DLT, mirroring a similar 33% cutoff as the previous 
studies. In the 2010 study by Toffoli et al8, MTD was defined as 
the level at which <2/10 patients experience DLT but in his 2017 
study, it was <4/10. Definitions for dose limiting toxicity were 
consistent between studies and included grade 3-4 diarrhea 
and neutropenia, as defined by the Common Terminology 
Criteria for Adverse Events.16  
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Figure III 
Design Schematic for 3+3 Phase I Study1 
 
 
   
The studies varied in the regimen of irinotecan used. Irinotecan 
monotherapy was only used in two studies, although frequency 
was every 14 days in one study and every 21 days in the other. 
10,13 Four studies used FOLFIRI, which is comprised of irinotecan 
administered every 2 weeks in combination with 5-fluorouracil 
and leucovorin. 8,9,14,15 However, in two of those studies, 
bevacizumab was concomitantly used. 14,15 Two studies 
included capecitabine.11,12 Kim et al12 studied XELIRI, which 
combines irinotecan and capecitabine alone while Goetz et al11 
studied CAPIRINOX, where irinotecan is administered with 
capecitabine and oxaliplatin. Starting doses used for patients 
with homozygous variant alleles ranged from 75 – 240 mg/m2, 
depending on the regimen. The lowest MTD for *28/*28 was 
reported in Marcuello et al9 and Goetz et al11 at 90 mg/m2 and 
75 mg/m2 respectively, although different regimens were used. 
Satoh et al10 determined MTD to be 150 mg/m2 for *6 and *28 
homozygous genotypes. Higher MTDs were observed in Lu et 
al14 and Kim et al.12 Lu et al14 determined MTD to be 210 mg/m2 
for *28/*28 genotypes, while Kim et al12 determined MTD to be 
240 mg/m2 for *6 and *28 homozygous genotypes. Innocenti et 
al13 utilized flat dosing based on a standard body surface area 
(BSA) of 1.8 m2  and determined MTD for *28/*28 to be 400 mg 
(equivalent to 220 mg/m2) when irinotecan was used as 
monotherapy administered every 3 weeks. In all studies, MTD 
for wild type alleles was higher than for homozygous variant 
alleles. The two studies by Toffoli et al8,15 only investigated the 
*1/*28 genotypes compared to wild-type and found that 
patients with only one variant allele require lower irinotecan 
doses as well.  
 
Tumor response was also evaluated in six studies as a secondary 
endpoint. 8,9,11-13,15 In the Kim et al12 and Marcuello et al9 
studies, overall response rate (ORR) decreased in patients who 
had two variant alleles (either *6 or *28). In Kim et al, patients 
with a wild-type allele had an ORR of 61.5%, which decreased 
to 28.6% in patients with 2 variant alleles. However, patients 
with one variant allele had an increased ORR of 80%. In 
Marcuello et al, the ORR for *1/*1, *1/*28 and *28/*28 
genotypes were 60%, 39% and 13%, respectively. In the other 
four studies, tumor response was either not correlated with 
genotype or efficacy results were inconclusive. (Table II) 
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Table II 
Summary of Results 
 
Name (year) Study Population Sample 
Size 
Genotypes 
Included 
Regimen Results (reported as MTD) 
Toffoli et al8  
(2010) 
Patients with 
mCRC 
n = 59 
  
UGT1A1 
*1/*1, *1/*28 
FOLFIRI *1/*1 - 370 mg/m2 
*1/*28 - 310 mg/m2 
Marcuello et al9 
(2011) 
Patients with 
mCRC or locally 
advanced 
recurrence after 
surgery 
n = 94 
  
UGT1A1 
*1/*1, *1/*28, 
*28/*28 
FOLFIRI *1/*1 - 180 mg/m2 
*1/*28 - 110 mg/m2 
*28/*28 - 90 mg/m2 
Satoh et al10  
(2011) 
Patients with 
histologically 
confirmed and 
inoperable  
mCRC 
n = 82 
  
UGT1A1 
*1/*1, *1/*28, 
*1/*6, 
*28/*28, 
*6/*6 
Irinotecan 
monotherapy 
every 14 days  
*1/*1, > 150 mg/m2 
*1/*6, *1/*28 - > 150 mg/m2 
*6/*6, *28/*28 - 150 mg/m2 
Goetz et al11  
(2013) 
Patients with 
metastatic or 
locally advanced 
cancer 
n = 53 
  
UGT1A1 
*1/*1, *1/*28, 
*28/*28 
CAPIRINOX *1/*1 – irinotecan 150 mg/m2, 
oxaliplatin 100 mg/m2, capecitabine 
1600 mg/m2 
  
*1/*28 - irinotecan 150 mg/m2, 
oxaliplatin 85 mg/m2, capecitabine 
400 mg/m2 
  
*28/*28 - irinotecan 75 mg/m2, 
oxaliplatin 85 mg/m2, capecitabine 
400 mg/m2 
Kim et al12  
(2013) 
Patients with 
mCRC 
n = 50 
  
UGT1A1 
*1/*1, *1/*28, 
*1/*6, 
*28/*28, 
*6/*6, *6/*28 
XELIRI *1/*1 - 380 mg/m2 
*1/*6,*1/*28 - 380 mg/m2 
*6/*6, *6/*28,*28/*28 - 240 
mg/m2 
Innocenti et al13 
(2014) 
Patients with 
histologically 
confirmed solid 
tumors or 
lymphoma 
refractory to 
standard therapy 
n = 68 
  
UGT1A1 
*1/*1, *1/*28, 
*28/*28 
Irinotecan 
monotherapy 
every 21 days 
*1/*1 – 850 mg (470 mg/m2*) 
*1/*28 – 700 mg (390 mg/m2*) 
*28/*28 – 400 mg (220 mg/m2*) 
 
 
*based on a standardized BSA of 
1.8 m2 
Lu et al14  
(2014) 
Patients with 
mCRC 
n = 107 
  
UGT1A1 
*1/*1, *1/*28, 
*28/*28 
FOLFIRI + 
bevacizumab 
*1/*1 - 260 mg/m2 
*1/*28 - 240 mg/m2 
*28/*28 - 210 mg/m2 
Toffoli et al15  
(2017) 
Patients with 
mCRC 
n = 48 UGT1A1 
*1/*1, *1/*28 
FOLFIRI + 
bevacizumab 
*1/*1 - 310 mg/m2 
*1/*28 - 260 mg/m2 
FOLFIRI – Irinotecan + leucovorin + 5-fluorouracil, irinotecan administered every 14 days 
CAPIRINOX – capecitabine + irinotecan + oxaliplatin, irinotecan administered every 21 days 
XELIRI – capecitabine + irinotecan, irinotecan administered every 21 days 
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Discussion 
Although the FDA label did not provide specific guidance for 
dosage adjustment, the Dutch Pharmacogenomics Working 
Group (DPWG) recommended to reduce the initial starting dose 
of irinotecan by 30% of the standard dose if the patient has a 
homozygous variant genotype.18 However, the difference in 
MTD for wild type vs. homozygous variant genotype seen in the 
studies of this review was often greater than 30%, suggesting a 
more conservative initial dose may be warranted. Furthermore, 
neither the FDA nor the DPWG addressed *6 alleles. The studies 
included in this review investigated patients with both *28 and 
*6 genotypes, which may allow for increased generalizability. 
The studies did not address any significant differences in 
response to irinotecan between *6/*6 vs. *28/*28 genotypes, 
so it may be reasonable to treat these patients similarly 
although more literature would be required to provide a 
complete comparison.  
 
Dosing recommendations ranged widely between the studies 
examined in this review. Much of the variability may be 
attributed to the heterogeneity of the studies with respect to 
the demographics of the study samples, the definitions used for 
MTD and the chemotherapy regimen utilized. The inclusion and 
exclusion criteria varied between the studies. An Eastern 
Cooperative Oncology Group (ECOG)19 score of 0-2 was a 
requirement for eligibility for most studies (although some used 
0-1) but patients’ various comorbidities may have influenced 
tolerance of irinotecan since not all studies excluded the same 
conditions. Concomitant use of chemotherapy agents in the 
regimen that also are associated with severe neutropenia and 
diarrhea may decrease the tolerability of irinotecan. For 
example, irinotecan dosing recommendations were lowest in 
the study by Goetz et al13 which may be due to the concomitant 
administration of oxaliplatin and capecitabine which can also 
both significantly contribute to neutropenia.  
 
Frequency of administration may also affect recommended 
doses. A review by Hoskins et al found that irinotecan toxicity 
was not associated with genotype at lower doses, such as < 150 
mg/m2.20 Similarly, a meta-analysis by Hu et al found that there 
was no association between genotype and irinotecan induced 
diarrhea at irinotecan doses < 125 mg/m2.21 This suggests that 
genotype may not be as significant of a factor for regimens 
where irinotecan is given weekly since doses tend to be lower 
than with regimens where irinotecan is administered every 2 or 
3 weeks.  
 
Several studies in this review also performed tumor response 
assessments and found that response rate was lower with the 
reduced doses recommended for variant allele genotypes. 
Therefore, it is also essential to ensure efficacy is not 
compromised when adjusting the dose based on genotype. 
Although more studies that are designed to evaluate efficacy 
are needed to fully understand the relationship, clinicians may 
choose to initiate treatment at doses higher than the MTDs 
established in these studies and utilize supportive care to 
manage adverse effects rather than risk inadequate response 
with lower dosages. Moreover, a secondary finding from this 
literature review was that the MTDs for patients with wild-type 
alleles were often significantly higher than standard doses of 
irinotecan. This suggests that these patients may be able to 
tolerate doses higher than what is used in clinical practice, 
which may lead to increased tumor responses.  
 
If patients are known to have homozygous variant alleles, it may 
be appropriate to utilize alternative therapies if available to 
decrease risk of an unfavorable safety profile or inadequate 
response. However, irinotecan is an inexpensive and widely 
used cytotoxic agent that is first line therapy for various 
cancers, such as mCRC. The benefits of use, even in 
homozygous *6 or *28 patients, may outweigh the risks as long 
as patients are carefully managed with supportive care.  
 
Conclusion 
These findings add to a growing body of literature that suggests 
patients with UGT1A1 *6 or *28 variant alleles benefit from 
lower doses of irinotecan. However, due to the heterogeneity 
of currently available studies, more evidence that investigates 
various regimens in different patient populations is needed to 
determine the most appropriate dosing strategies. Although 
other factors as well as efficacy considerations will likely 
influence clinical decision making, genotype may be an 
important factor when determining dose. As the field of 
pharmacogenomics rapidly advances, further developments in 
the literature driven by more robust studies will serve to guide 
clinicians with regard to UGT1A1 genotypes and lead to 
improved patient outcomes.  
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